Author name: Nancy Elmahdy

New FDA Draft Guidance on Decentralized Clinical Trials

Delve Health Comments on FDA Draft Guidance on Decentralized Clinical Trials for Drugs and Biological Products

Our Review of the New FDA Draft Guidance Decentralized clinical trials (DCTs) have become increasingly popular in recent years due to their potential to increase patient access and reduce the burden of participating in clinical trials. In response to this trend, the US Food & Drug Administration (FDA) has issued new guidance on the use […]

Delve Health Comments on FDA Draft Guidance on Decentralized Clinical Trials for Drugs and Biological Products Read More »

Delve Health and cerascreen announce their partnership in digital healthcare

Delve Health and cerascreen Announce a Partnership to Offer a “One-Stop Solution” Digital Healthcare App

FOR IMMEDIATE RELEASE: May 11, 2023 CONTACT:+1.952.200.6228media@delvehealth.com Minneapolis, MN – Delve Health, a virtual health and technology firm, and cerascreen®, an at-home health diagnostic testing company, are announcing an exciting partnership to expand access to digital healthcare solutions worldwide via smart and wearable devices (e.g., smart phones, tablets, wrist wearables, etc.). Delve Health provides a

Delve Health and cerascreen Announce a Partnership to Offer a “One-Stop Solution” Digital Healthcare App Read More »

Delve Health's platform leverages digital endpoints, collected from smartphones and multiple wearable devices, to support your clinical trial.

Digital Endpoints Have a Positive Effect on Clinical Trials

The use of technology has been increasing over the past few years, with devices such as wearables, biosensors, and other medical devices. One area where this has been particularly evident is the use of digital endpoints in clinical trials. Digital endpoints refer to data collected from digital sources, such as mobile apps and passively collected

Digital Endpoints Have a Positive Effect on Clinical Trials Read More »

Scroll to Top